Implantable microdevices for treating brain tumors

Ostrom, 2020, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017, Neuro Oncol., 22, iv1, 10.1093/neuonc/noaa200 2022 Poon, 2020, Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis, Sci. Rep., 10, 10.1038/s41598-020-68011-4 Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med., 352, 987, 10.1056/NEJMoa043330 Rong, 2022, Emerging therapies for glioblastoma: current state and future directions, J. Exp. Clin. Cancer Res., 41, 142, 10.1186/s13046-022-02349-7 Rominiyi, 2021, Tumour treating fields therapy for glioblastoma: current advances and future directions, Br. J. Cancer, 124, 697, 10.1038/s41416-020-01136-5 Stupp, 2017, Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial, JAMA, 318, 2306, 10.1001/jama.2017.18718 Stupp, 2015, Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial, JAMA, 314, 2535, 10.1001/jama.2015.16669 Shergalis, 2018, Current Challenges and Opportunities in Treating Glioblastoma, Pharmacol. Rev., 70, 412, 10.1124/pr.117.014944 Reardon, 2013, A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma, Clin. Cancer Res., 19, 900, 10.1158/1078-0432.CCR-12-1707 Wen, 2020, Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions, Neuro Oncol., 22, 1073, 10.1093/neuonc/noaa106 Bastiancich, 2021, Rationally designed drug delivery systems for the local treatment of resected glioblastoma, Adv. Drug Deliv. Rev., 177, 10.1016/j.addr.2021.113951 Laquintana, 2009, New strategies to deliver anticancer drugs to brain tumors, Expet Opin. Drug Deliv., 6, 1017, 10.1517/17425240903167942 Westphal, 2003, A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neuro Oncol., 5, 79, 10.1093/neuonc/5.2.79 Brem, 2007, Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model, Cancer Chemother. Pharmacol., 60, 643, 10.1007/s00280-006-0407-2 Valtonen, 1997, Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study, Neurosurgery, 41, 44, 10.1097/00006123-199707000-00011 Wu, 2022, Implantable Polyurethane Scaffolds Loading with PEG-Paclitaxel Conjugates for the Treatment of Glioblastoma Multiforme, Chin. J. Polym. Sci., 40, 491, 10.1007/s10118-022-2695-3 Zhao, 2019, A Meta-Analysis of Survival Outcomes Following Reoperation in Recurrent Glioblastoma: Time to Consider the Timing of Reoperation, Front. Neurol., 10, 286, 10.3389/fneur.2019.00286 Chaichana, 2011, The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival, Neurol. Res., 33, 759, 10.1179/1743132811Y.0000000006 Affronti, 2009, Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy, Cancer, 115, 3501, 10.1002/cncr.24398 Chen, 2020, A basal-bolus insulin regimen integrated microneedle patch for intraday postprandial glucose control, Sci. Adv., 6, eaba7260, 10.1126/sciadv.aba7260 Wait, 2015, Polymeric drug delivery for the treatment of glioblastoma, Neuro Oncol., 17, ii9, 10.1093/neuonc/nou360 Alfarouk, 2015, Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp, Cancer Cell Int., 15, 71, 10.1186/s12935-015-0221-1 Lathia, 2015, Cancer stem cells in glioblastoma, Genes Dev., 29, 1203, 10.1101/gad.261982.115 Jonas, 2016, First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development, J. Biomed. Nanotechnol., 12, 1297, 10.1166/jbn.2016.2262 Scott, 2011, Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model, Biomaterials, 32, 2532, 10.1016/j.biomaterials.2010.12.020 Wang, 2022, Silk Microneedle Patch Capable of On-Demand Multidrug Delivery to the Brain for Glioblastoma Treatment, Adv. Mater., 34 Masi, 2012, Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model, Biomaterials, 33, 5768, 10.1016/j.biomaterials.2012.04.048 Lee, 2019, Flexible, sticky, and biodegradable wireless device for drug delivery to brain tumors, Nat. Commun., 10, 5205, 10.1038/s41467-019-13198-y Yao, 2022, Self-Powered, Implantable, and Wirelessly Controlled NO Generation System for Intracranial Neuroglioma Therapy, Adv. Mater., 34, 10.1002/adma.202205881 Su, 2021, PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application, Drug Deliv., 28, 1397, 10.1080/10717544.2021.1938756 Alghamdi, 2021, Local delivery to malignant brain tumors: potential biomaterial-based therapeutic/adjuvant strategies, Biomater. Sci., 9, 6037, 10.1039/D1BM00896J Cheng, 2014, Multifunctional nanoparticles for brain tumor imaging and therapy, Adv. Drug Deliv. Rev., 66, 42, 10.1016/j.addr.2013.09.006 McCrorie, 2020, Biomedical engineering approaches to enhance therapeutic delivery for malignant glioma, J. Contr. Release, 328, 917, 10.1016/j.jconrel.2020.11.022 Nduom, 2012, Nanotechnology applications for glioblastoma, Neurosurg. Clin., 23, 439, 10.1016/j.nec.2012.04.006 Page, 2021, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 372, n71, 10.1136/bmj.n71 Mahmood, 2011, Optimizing clinical performance and geometrical robustness of a new electrode device for intracranial tumor electroporation, Bioelectrochemistry, 81, 10, 10.1016/j.bioelechem.2010.12.002 Shapira-Furman, 2019, Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer, J. Contr. Release, 295, 93, 10.1016/j.jconrel.2018.12.048 Pan, 2022, Biodegradable controlled-release polymer containing butylidenephthalide to treat a recurrent cervical spine glioblastoma with promising result: a compassionate trial report, Anti Cancer Drugs, 33, 394, 10.1097/CAD.0000000000001275 Ranganath, 2009, Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour chemotherapy, Pharm. Res. (N. Y.), 26, 2101, 10.1007/s11095-009-9922-2 Carpentier, 2016, Clinical trial of blood-brain barrier disruption by pulsed ultrasound, Sci. Transl. Med., 8, 343re2, 10.1126/scitranslmed.aaf6086 Kim, 2012, MRI-monitored long-term therapeutic hydrogel system for brain tumors without surgical resection, Biomaterials, 33, 4836, 10.1016/j.biomaterials.2012.03.048 Shi, 2016, Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model, Invest. N. Drugs, 34, 269, 10.1007/s10637-016-0340-0 Upadhyay, 2014, Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain, Proc. Natl. Acad. Sci. USA, 111, 16071, 10.1073/pnas.1313420110 Kim, 2007, Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model, J. Contr. Release, 123, 172, 10.1016/j.jconrel.2007.08.003 Giussani, 2003, Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo, Cancer Res., 63, 2499 Wang, 2018, Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model, J. Neurosurg., 128, 695, 10.3171/2016.11.JNS161212 Sonabend, 2014, Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma, Neuro Oncol., 16, 1210, 10.1093/neuonc/nou026 Wang, 2015, Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals, Neurosurg. Focus, 38, E8, 10.3171/2015.1.FOCUS14743 Yoshimura, 2012, The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model, Childs Nerv. Syst., 28, 707, 10.1007/s00381-012-1732-x Zamykal, 2015, Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms, Neuro Oncol., 17, 1076, 10.1093/neuonc/nou344 Mairs, 2000, Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model, Br. J. Cancer, 82, 74, 10.1054/bjoc.1999.0879 Ding, 2010, Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1, J. Neuro Oncol., 98, 1, 10.1007/s11060-009-0046-7 Ding, 2010, Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321, Neurol. Res., 32, 810 Huang, 2015, A novel brain metastasis xenograft model for convection-enhanced delivery of targeted toxins via a micro-osmotic pump system enabled for real-time bioluminescence imaging, Mol. Med. Rep., 12, 5163, 10.3892/mmr.2015.4111 Ozawa, 2005, Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model, Int. J. Radiat. Oncol. Biol. Phys., 63, 247, 10.1016/j.ijrobp.2005.05.030 Rousseau, 2009, Efficacy of intracerebral delivery of Carboplatin in combination with photon irradiation for treatment of F98 glioma-bearing rats, Int. J. Radiat. Oncol. Biol. Phys., 73, 530, 10.1016/j.ijrobp.2008.09.018 Rechberger, 2020, Evaluating infusate parameters for direct drug delivery to the brainstem: a comparative study of convection-enhanced delivery versus osmotic pump delivery, Neurosurg. Focus, 48, E2, 10.3171/2019.10.FOCUS19703 D'Amico, 2019, Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model, J. Neurosurg., 151, 1 Halle, 2016, Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept, J. Neuro Oncol., 126, 47, 10.1007/s11060-015-1947-2 Thisgaard, 2016, Highly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenograft Model using Convection-Enhanced Delivery, Theranostics, 6, 2278, 10.7150/thno.15898 Sonabend, 2011, Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump, Neuro Oncol., 13, 886, 10.1093/neuonc/nor051 Fan, 2015, Continuous intraputamenal convection-enhanced delivery in adult rhesus macaques, J. Neurosurg., 123, 1569, 10.3171/2015.1.JNS132345 Spinazzi, 2022, Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial, Lancet Oncol., 23, 1409, 10.1016/S1470-2045(22)00599-X Jonas, 2015, An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors, Sci. Transl. Med., 7, 284ra57, 10.1126/scitranslmed.3010564 Richards Grayson, 2003, Multi-pulse drug delivery from a resorbable polymeric microchip device, Nat. Mater., 2, 767, 10.1038/nmat998 2023 2020 Almoshari, 2022, Osmotic Pump Drug Delivery Systems-A Comprehensive Review, Pharmaceuticals, 15, 1430, 10.3390/ph15111430 Klespitz, 2014, Peristaltic pumps — A review on working and control possibilities, 191 Das, 2020, Biointegrated and Wirelessly Powered Implantable Brain Devices: A Review, IEEE Trans. Biomed. Circuits Syst., 14, 343, 10.1109/TBCAS.2020.2966920 Marcucci, 2021, Breaching the Blood–Brain Tumor Barrier for Tumor Therapy, Cancers, 13, 2391, 10.3390/cancers13102391 Bayat Mokhtari, 2017, Combination therapy in combating cancer, Oncotarget, 8, 38022, 10.18632/oncotarget.16723 Al-Lazikani, 2012, Combinatorial drug therapy for cancer in the post-genomic era, Nat. Biotechnol., 30, 679, 10.1038/nbt.2284 Falchook, 2010, A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib, J. Clin. Oncol., 28, 2512, 10.1200/jco.2010.28.15_suppl.2512 Taal, 2014, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol., 15, 943, 10.1016/S1470-2045(14)70314-6 Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J. Clin. Oncol., 27, 4733, 10.1200/JCO.2008.19.8721 Bota, 2018, Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts, CNS Oncol., 7, Cns22, 10.2217/cns-2018-0009 Dymova, 2021, Molecular Mechanisms of Drug Resistance in Glioblastoma, Int. J. Mol. Sci., 22, 6385, 10.3390/ijms22126385 Aldape, 2019, Challenges to curing primary brain tumours, Nat. Rev. Clin. Oncol., 16, 509, 10.1038/s41571-019-0177-5 Neftel, 2019, An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma, Cell, 178, 835, 10.1016/j.cell.2019.06.024 Becker, 2021, Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology, Cancers, 13, 10.3390/cancers13040761 Aquilanti, 2022, Current therapeutic options for glioblastoma and future perspectives, Expet Opin. Pharmacother., 23, 1629, 10.1080/14656566.2022.2125302 Prados, 2015, Toward precision medicine in glioblastoma: the promise and the challenges, Neuro Oncol., 17, 1051, 10.1093/neuonc/nov031 Hoare, 2008, Hydrogels in drug delivery: Progress and challenges, Polymer, 49, 1993, 10.1016/j.polymer.2008.01.027 Rapeaux, 2021, Implantable brain machine interfaces: first-in-human studies, technology challenges and trends, Curr. Opin. Biotechnol., 72, 102, 10.1016/j.copbio.2021.10.001 Chaichana, 2013, Multiple resections for patients with glioblastoma: prolonging survival, J. Neurosurg., 118, 812, 10.3171/2012.9.JNS1277 Jankun, 2012, Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: A case report, Exp. Ther. Med., 4, 661, 10.3892/etm.2012.639 Di Trani, 2022, Extending drug release from implants via transcutaneous refilling with solid therapeutics, Adv. Ther., 5 Gómez-Oliva, 2021, Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments, Front. Oncol., 10, 10.3389/fonc.2020.614295 Kijima, 2017, Mouse Models of Glioblastoma Ernst, 2009, Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival, Clin. Cancer Res., 15, 6541, 10.1158/1078-0432.CCR-09-0695 Haddad, 2021, Mouse models of glioblastoma for the evaluation of novel therapeutic strategies, Neurooncol. Adv., 3, vdab100 Welniak-Kaminska, 2019, Volumes of brain structures in captive wild-type and laboratory rats: 7T magnetic resonance in vivo automatic atlas-based study, PLoS One, 14, 10.1371/journal.pone.0215348 Yu, 2014, Deciphering laminar-specific neural inputs with line-scanning fMRI, Nat. Methods, 11, 55, 10.1038/nmeth.2730 2023